Login to Your Account

BioSante $45M Offering to Fund Phase III Libigel Development

By Catherine Shaffer

Friday, July 29, 2011
A $45 million public offering by BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., will help float the company through Phase III Libigel trials. Libigel is a transdermal testosterone gel that BioSante is developing for female sexual dysfunction.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription